Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

ClinicalTrials.gov ID: NCT01086540

Public ClinicalTrials.gov record NCT01086540. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Study identification

NCT ID: NCT01086540
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Enrollment: 57 participants

Conditions and interventions

Conditions

Systemic Sclerosis-Associated PAH

Interventions

Rituximab Biological
Placebo Other
CMRI Diagnostic Test
prednisone Drug
methylprednisolone Drug
diphenhydramine Drug
acetaminophen Drug

Biological · Other · Diagnostic Test + 1 more

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 23, 2011
Primary completion: Jun 4, 2018
Completion: Dec 14, 2019
Last update posted: Feb 20, 2023

2011 – 2019

United States locations

U.S. sites: 17
U.S. states: 14
U.S. cities: 16

Facility	City	State	ZIP	Site status
Stanford Health Care	Stanford	California	94305	—
University of Colorado Health Sciences Center	Aurora	Colorado	80045	—
University of Iowa	Iowa City	Iowa	52242	—
Johns Hopkins University, Pulmonary and Critical Care Medicine	Baltimore	Maryland	21205	—
Boston University Medical Center	Boston	Massachusetts	02118	—
University of Michigan	Ann Arbor	Michigan	48109	—
University of Minnesota Health Clinics and Surgery Center	Minneapolis	Minnesota	55455	—
Columbia University Medical Center	New York	New York	10032	—
Weill Cornell Medical College	New York	New York	10065	—
University of Rochester Medical Center	Rochester	New York	14642	—
University of North Carolina at Chapel Hill: UNC Hospitals	Chapel Hill	North Carolina	27514	—
Ohio State University	Columbus	Ohio	43210	—
University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania	15261	—
Medical University of South Carolina	Charleston	South Carolina	29425	—
University of Texas Southwestern Medical Center-William P. Clements University Hospital	Dallas	Texas	75390	—
University of Texas: Memorial Herman Hospital	Houston	Texas	77030	—
University of Utah	Salt Lake City	Utah	84132	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01086540, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 20, 2023 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01086540 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →